Karyopharm Therapeutics Inc
$ 4.24
-11.11%
15 Jul - close price
- Market Cap 36,633,200 USD
- Current Price $ 4.24
- High / Low $ 4.97 / 4.10
- Stock P/E N/A
- Book Value -24.03
- EPS -11.87
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -8.91 %
- 52 Week High 16.95
- 52 Week Low 3.51
About
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Analyst Target Price
$29.25
Quarterly Earnings
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-05-06 | 2025-02-26 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-04 | 2023-02-15 | 2022-11-03 | 2022-08-04 |
| Reported EPS | -2.77 | -0.24 | -0.2566 | 0.15 | -0.32 | -0.36 | -0.3 | -0.29 | -0.3 | -0.43 | -0.45 | -0.62 |
| Estimated EPS | -3.0888 | -0.2688 | -0.26 | -0.3 | -0.33 | -0.31 | -0.28 | -0.34 | -0.37 | -0.35 | -0.57 | -0.63 |
| Surprise | 0.3188 | 0.0288 | 0.0034 | 0.45 | 0.01 | -0.05 | -0.02 | 0.05 | 0.07 | -0.08 | 0.12 | 0.01 |
| Surprise Percentage | 10.3212% | 10.7143% | 1.3077% | 150% | 3.0303% | -16.129% | -7.1429% | 14.7059% | 18.9189% | -22.8571% | 21.0526% | 1.5873% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2025-05-26 13:55:05
Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2025-05-19 13:55:06
The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
2025-05-13 17:39:58
Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday. The company posted quarterly losses of $2.77 per share which beat the analyst consensus estimate of losses of $4.16 per share.
2025-05-12 21:25:08
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 34.20% and 16.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
2025-05-05 21:10:03
Neurocrine (NBIX) delivered earnings and revenue surprises of -81.40% and 2.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
2025-04-08 09:02:57
Shares of Levi Strauss & Co. LEVI rose sharply in today's pre-market trading after reported better-than-expected earnings for its first quarter on Monday. Levi Strauss & Co. reported quarterly adjusted earnings of 38 cents per share, which beat the 28 cent analyst consensus estimate.
